For decades, ultrasound has been used to image organs such as the heart and kidneys, check blood flow, monitor the development of fetuses, reduce pain and even break up kidney stones.
Now, a Norwegian biotech company called Phoenix Solutions AS is working with the Translational Genomics Research Institute (TGen), a Phoenix, Arizona-based biomedical research facility, to test the use of these pulsed sound waves to direct and focus cancer drug therapies.
In laboratory tests, TGen will help analyze the effectiveness of a technology called Acoustic Cluster Therapy (ACT), a unique approach to targeting cancer cells by concentrating the delivery of chemotherapies, making them more effective and potentially reducing their toxicity.
Humanscan Co. Ltd., a South Korean manufacture of ultrasound diagnostic imaging, is developing clinically applicable hardware optimized for ACT, which TGen will then validate.
Phoenix Solutions is using funding from Innovation Norway to conduct this research in advance of pancreatic cancer clinical trials planned later this year.
“We are very pleased to receive this grant, which will enable us to develop and validate an optimal ultrasound platform for clinical use of ACT. In their respective fields, Humanscan and TGen both represent the cutting edge of science, and we are confident this will contribute to the clinical success of our program,” said Dr. Per Sontum, CEO of Phoenix Solutions.
TGen is a world leader in the development of novel therapeutics for the treatment of pancreatic cancer. The TGen team led the clinical development of one of the current standard-of-care regimens for this disease — nab-paclitaxel plus gemcitabine. TGen currently is involved in 13 pancreatic cancer clinical programs.
“We are pleased that this research program has become a reality, and look forward to working with ACT. The concept represents a novel approach to targeted drug delivery and looks very promising,” said Dr. Haiyong Han, a Professor in TGen’s Molecular Medicine Division and head of the Basic Research Unit in TGen’s Pancreatic Cancer Program.
Among the advantages of ultrasound technology: it is generally painless; non-invasive; does not require needles, injections or incisions; and patients are not exposed to ionizing radiation, making the procedure safer than diagnostic techniques such as X-rays and CT scans.
Humanscan CEO Sungmin Rhim said, “We are excited to enter into this collaboration with Phoenix (Solutions) and participate in the development of ACT. Ultrasound mediated, targeted drug delivery is an emerging therapy approach with great potential and we are delighted to be in the forefront of this development.”
Phoenix Solutions also is considering this technology for use in addressing other types of cancer, including: liver, prostate and triple-negative breast cancer; and other diseases, including those involving inflammation and the central nervous system.
Learn more: TGEN TESTS ULTRASOUND AS WAY TO ENHANCE CANCER DRUG DELIVERY
The Latest on: Cancer drug delivery
[google_news title=”” keyword=”cancer drug delivery” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Cancer drug delivery
- Drug Delivery Technologies market is projected to grow at a CAGR of 5.5% by 2034: Visiongainon April 26, 2024 at 6:15 am
Visiongain has published a new report entitled Drug Delivery Technologies Market Report 2024-2034: Forecasts by Route of Administration (Implantable Drug Delivery, Injectable Drug Delivery Nasal Drug ...
- MIT Develops Closed-Loop Drug Delivery System to Enhance Chemotherapyon April 24, 2024 at 5:37 pm
When cancer patients undergo chemotherapy, the dose of most drugs is calculated based on the patient’s body surface area. This is estimated by plugging the patient’s height and weight into an equation ...
- A closed-loop drug-delivery system could improve chemotherapyon April 24, 2024 at 2:02 pm
When cancer patients undergo chemotherapy, the dose of most drugs is calculated based on the patient's body surface area. This is estimated by plugging the patient's height and weight into an equation ...
- Endeavor raises $132.5m for fibrosis, cancer drugson April 24, 2024 at 9:47 am
Endeavor BioMedicines has completed a third round financing, raising an impressive $132.5 million to fund trials of its two clinical-stage drug candidates for pulmonary fibrosis and solid tumours.
- Cancer Cells Give Orderson April 23, 2024 at 7:51 am
It is] interesting work that further highlights the complex intercellular crosstalk between stromal cells in cancer,” said Giulia Biffi, a cancer biologist at the University of Cambridge who was not ...
- Collaboration and Partnerships in Accelerating Cancer Drug Developmenton April 23, 2024 at 5:53 am
Lorna Rothery spoke to the Cancer Drug Development Forum’s Managing Director, Professor Jaap Verweij and Chairperson of the CDDF Board of Directors, Professor Ruth Plummer, about opportunities and cha ...
- Injectable Drug Delivery Market To Reach USD 1,714.8 Billion By 2032, Says DataHorizzon Researchon April 22, 2024 at 10:30 pm
The Injectable Drug Delivery market size was valued at USD 668.2 Billion in 2023 and is expected to reach a market size of USD 1,714.8 Billion by 2032 at a CAGR of 11.1%.Fort Collins, Colorado, April ...
- Cancer Breakthrough Found to Boost Immune Cells Without Harmful Side-Effects By Directing Protein Cytokineson April 21, 2024 at 7:00 am
A new way to safely boost immune cells to fight cancer—avoiding harmful side-effects such as hair loss—has been developed.
- Next-generation treatments hitch a ride into cancer cellson April 20, 2024 at 11:06 am
Researchers found that a new activator called L687 induces cancer cells to accept delivery of antisense oligonucleotide (ASO) drugs. These drugs can treat cancer by blocking the transfer of messages ...
via Bing News